Therapeutic mainstays like oncology and neuroscience have hogged the spotlight lately. With flashy billion-dollar acquisitions and groundbreaking drugs for diseases like Alzheimer’s and various cancers, who could look away? Big players like Johnson & Johnson haven’t been shy, forking over a hefty sum of $14.6 billion for neuropsychiatric leader Intra-Cellular Therapies. But wait, 2025 might […]
- Mon - Sat: 8.00 - 18.00
- 1-12-32 Akasaka, Minato-ku Tokyo, Japan